MedTrace Logo

A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR

NCT00334347 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2007-12-06

No results posted yet for this study

Summary

To compare the time to response, response rates, remission rates, and side effects in Bipolar Disorder inpatients treated with Depakote ER or Depakote DR for acute mania or mixed mania.

Conditions

Interventions

DRUG

Depakote ER

The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.

DRUG

Depakote DR

The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • John D Matthews, M.D. · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334347 on ClinicalTrials.gov